Real-world Drug Survival of Guselkumab in Patients With Psoriasis Stratified by Weight and Comorbidities: Retrospective, Observational Data From the British Association of Dermatologists Biologics and Immunomodulators Register

Vollständiger Abstract

Worum geht es in dieser Arbeit?

Abstract In the United Kingdom (UK), 89.1% of patients with moderate-to-severe psoriasis are overweight or obese, and 53.2% have at least one comorbidity. However, real-world data on biologic-treated patients with psoriasis and comorbidities remains limited. Objectives were to compare 36-month drug survival of guselkumab in patients across weight and body mass index (BMI) categories, and in those with or without specific comorbidities. This retrospective cohort study used data from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR), collected from January 2018 to July 2024. Co-primary outcomes were overall drug survival, and drug survival stratified by weight and BMI categories, over 36 months, for guselkumab-treated patients. Secondary outcomes included 36-month drug survival among guselkumab-treated patients with and without specific comorbidities, including but not limited to, metabolic syndrome, hypertension, anxiety and/or depression. Kaplan–Meier methodology was used to estimate probabilities for time-to-treatment discontinuation across all patient groups analysed. Among the 482 participants included in this analysis who initiated guselkumab treatment, 36-month drug survival was generally high, with an overall drug survival rate of 0.75 (95% CI, 0.71–0.79). Stratified by weight, drug survival rates were 0.71 (95% CI, 0.59–0.86) for patients